These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 9663825)

  • 1. Treatment of ulcerative colitis with an engineered human anti-TNFalpha antibody CDP571.
    Evans RC; Clarke L; Heath P; Stephens S; Morris AI; Rhodes JM
    Aliment Pharmacol Ther; 1997 Dec; 11(6):1031-5. PubMed ID: 9663825
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CDP571, a humanised monoclonal antibody to tumour necrosis factor alpha, for moderate to severe Crohn's disease: a randomised, double blind, placebo controlled trial.
    Sandborn WJ; Feagan BG; Radford-Smith G; Kovacs A; Enns R; Innes A; Patel J
    Gut; 2004 Oct; 53(10):1485-93. PubMed ID: 15361500
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomised controlled trial of CDP571 antibody to tumour necrosis factor-alpha in Crohn's disease.
    Stack WA; Mann SD; Roy AJ; Heath P; Sopwith M; Freeman J; Holmes G; Long R; Forbes A; Kamm MA
    Lancet; 1997 Feb; 349(9051):521-4. PubMed ID: 9048788
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, for steroid-dependent Crohn's disease: a randomized, double-blind, placebo-controlled trial.
    Feagan BG; Sandborn WJ; Lichtenstein G; Radford-Smith G; Patel J; Innes A
    Aliment Pharmacol Ther; 2006 Mar; 23(5):617-28. PubMed ID: 16480401
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.
    Chatzinasiou F; Polymeros D; Panagiotou M; Theodoropoulos K; Rigopoulos D
    Acta Dermatovenerol Croat; 2016 Apr; 24(1):83-5. PubMed ID: 27149138
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The therapeutic effects of an engineered human anti-tumour necrosis factor alpha antibody (CDP571) in rheumatoid arthritis.
    Rankin EC; Choy EH; Kassimos D; Kingsley GH; Sopwith AM; Isenberg DA; Panayi GS
    Br J Rheumatol; 1995 Apr; 34(4):334-42. PubMed ID: 7788147
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized, double-blind, placebo-controlled trial of CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, in patients with corticosteroid-dependent Crohn's disease.
    Feagan BG; Sandborn WJ; Baker JP; Cominelli F; Sutherland LR; Elson CO; Salzberg BA; Archambault A; Bernstein CN; Lichtenstein GR; Heath PK; Cameron S; Hanauer SB
    Aliment Pharmacol Ther; 2005 Feb; 21(4):373-84. PubMed ID: 15709987
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of ulcerative colitis in the cottontop tamarin using antibody to tumour necrosis factor alpha.
    Watkins PE; Warren BF; Stephens S; Ward P; Foulkes R
    Gut; 1997 May; 40(5):628-33. PubMed ID: 9203942
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CDP571, a humanized antibody to human tumor necrosis factor-alpha: safety, pharmacokinetics, immune response, and influence of the antibody on cytokine concentrations in patients with septic shock. CPD571 Sepsis Study Group.
    Dhainaut JF; Vincent JL; Richard C; Lejeune P; Martin C; Fierobe L; Stephens S; Ney UM; Sopwith M
    Crit Care Med; 1995 Sep; 23(9):1461-9. PubMed ID: 7664546
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravenous immunoglobulin therapy for active, extensive, and medically refractory idiopathic ulcerative or Crohn's colitis.
    Levine DS; Fischer SH; Christie DL; Haggitt RC; Ochs HD
    Am J Gastroenterol; 1992 Jan; 87(1):91-100. PubMed ID: 1728132
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CDP571, a humanized anti-tumor necrosis factor-alpha monoclonal antibody in pediatric Crohn's disease.
    Mamula P; Cohen SA; Ferry GD; Kirschner BS; Winter HS; Innes A; Patel J; Baldassano RN;
    Inflamm Bowel Dis; 2004 Nov; 10(6):723-30. PubMed ID: 15626889
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An engineered human antibody to TNF (CDP571) for active Crohn's disease: a randomized double-blind placebo-controlled trial.
    Sandborn WJ; Feagan BG; Hanauer SB; Present DH; Sutherland LR; Kamm MA; Wolf DC; Baker JP; Hawkey C; Archambault A; Bernstein CN; Novak C; Heath PK; Targan SR;
    Gastroenterology; 2001 May; 120(6):1330-8. PubMed ID: 11313302
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety.
    Sandborn WJ; Hanauer SB
    Inflamm Bowel Dis; 1999 May; 5(2):119-33. PubMed ID: 10338381
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A pilot study of treatment of active ulcerative colitis with natalizumab, a humanized monoclonal antibody to alpha-4 integrin.
    Gordon FH; Hamilton MI; Donoghue S; Greenlees C; Palmer T; Rowley-Jones D; Dhillon AP; Amlot PL; Pounder RE
    Aliment Pharmacol Ther; 2002 Apr; 16(4):699-705. PubMed ID: 11929387
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Treatment of ulcerative colitis and Crohn's disease with monoclonal antibody].
    Asakura H
    Nihon Rinsho; 2002 Mar; 60(3):531-8. PubMed ID: 11904969
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis.
    Sandborn WJ; Feagan BG; Marano C; Zhang H; Strauss R; Johanns J; Adedokun OJ; Guzzo C; Colombel JF; Reinisch W; Gibson PR; Collins J; Järnerot G; Rutgeerts P;
    Gastroenterology; 2014 Jan; 146(1):96-109.e1. PubMed ID: 23770005
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
    Magro F; Portela F
    BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The engineered human anti-tumor necrosis factor-alpha antibody CDP571 inhibits inflammatory pathways but not T cell activation in patients with rheumatoid arthritis.
    Choy EH; Rankin EC; Kassimos D; Vetterlein O; Garyfallos A; Ravirajan CT; Sopwith M; Eastell R; Kingsley GH; Isenberg DA; Panayi GS
    J Rheumatol; 1999 Nov; 26(11):2310-7. PubMed ID: 10555883
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of an engineered human anti-TNF-alpha antibody (CDP571) on insulin sensitivity and glycemic control in patients with NIDDM.
    Ofei F; Hurel S; Newkirk J; Sopwith M; Taylor R
    Diabetes; 1996 Jul; 45(7):881-5. PubMed ID: 8666137
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum concentrations after switching from originator infliximab to the biosimilar CT-P13 in patients with quiescent inflammatory bowel disease (SECURE): an open-label, multicentre, phase 4 non-inferiority trial.
    Strik AS; van de Vrie W; Bloemsaat-Minekus JPJ; Nurmohamed M; Bossuyt PJJ; Bodelier A; Rispens T; van Megen YJB; D'Haens GR;
    Lancet Gastroenterol Hepatol; 2018 Jun; 3(6):404-412. PubMed ID: 29606564
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.